Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1957 1
1962 1
1963 1
1964 1
1965 1
1968 4
1969 3
1971 3
1972 5
1973 3
1974 2
1975 3
1976 2
1977 4
1978 2
1979 8
1980 7
1981 8
1982 13
1983 6
1984 10
1985 12
1986 4
1987 13
1988 8
1989 20
1990 23
1991 18
1992 23
1993 30
1994 20
1995 35
1996 20
1997 33
1998 39
1999 24
2000 28
2001 27
2002 46
2003 63
2004 58
2005 63
2006 76
2007 96
2008 115
2009 119
2010 134
2011 166
2012 215
2013 221
2014 229
2015 256
2016 252
2017 244
2018 296
2019 300
2020 397
2021 415
2022 366
2023 385
2024 156

Text availability

Article attribute

Article type

Publication date

Search Results

4,496 results

Results by year

Filters applied: . Clear all
Page 1
A vertebral skeletal stem cell lineage driving metastasis.
Sun J, Hu L, Bok S, Yallowitz AR, Cung M, McCormick J, Zheng LJ, Debnath S, Niu Y, Tan AY, Lalani S, Morse KW, Shinn D, Pajak A, Hammad M, Suhardi VJ, Li Z, Li N, Wang L, Zou W, Mittal V, Bostrom MPG, Xu R, Iyer S, Greenblatt MB. Sun J, et al. Among authors: tan ay. Nature. 2023 Sep;621(7979):602-609. doi: 10.1038/s41586-023-06519-1. Epub 2023 Sep 13. Nature. 2023. PMID: 37704733 Free PMC article.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: tan a. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression.
Huang KK, Ma H, Chong RHH, Uchihara T, Lian BSX, Zhu F, Sheng T, Srivastava S, Tay ST, Sundar R, Tan ALK, Ong X, Lee M, Ho SWT, Lesluyes T, Ashktorab H, Smoot D, Van Loo P, Chua JS, Ramnarayanan K, Lau LHS, Gotoda T, Kim HS, Ang TL, Khor C, Lee JWJ, Tsao SKK, Yang WL, Teh M, Chung H, So JBY, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium. Huang KK, et al. Among authors: tan alk. Cancer Cell. 2023 Dec 11;41(12):2019-2037.e8. doi: 10.1016/j.ccell.2023.10.004. Epub 2023 Oct 26. Cancer Cell. 2023. PMID: 37890493 Free PMC article.
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: tan ac. Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012550 Free PMC article. Clinical Trial.
Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P; Singapore Gastric Cancer Consortium. Xu C, et al. Among authors: tan alk. Gut. 2023 Sep;72(9):1651-1663. doi: 10.1136/gutjnl-2022-328332. Epub 2023 Mar 14. Gut. 2023. PMID: 36918265
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. Aggarwal R, et al. Among authors: tan a. J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23. J Clin Oncol. 2024. PMID: 38261983 Clinical Trial.
Editorial: Women in science-Precision medicine 2021.
Chen AP, Tan A. Chen AP, et al. Among authors: tan a. Front Med (Lausanne). 2023 Jul 11;10:1218579. doi: 10.3389/fmed.2023.1218579. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37547600 Free PMC article. No abstract available.
4,496 results